Clinical Challenges with Neovascular Glaucoma-Patient Tailored Strategies and Outcomes
Main Article Content
Keywords
Neovascular Glaucoma, Retinal Ischemia, IOP, VEGF, Surgical Outcomes
Abstract
Background: To report the outcomes of patient-tailored concurrent combined surgery for retinal ischemia and intraocular pressure (IOP) control in neovascular glaucoma (NVG) with or without cataract.
Methodology: Patients with Ninety-seven (97) eyes with NVG seen between January 2022-September 2023 at a tertiary eye care centre were recruited for this study. Six (6) eyes (4 proliferative diabetic retinopathy and 2 retinal vein occlusions) that underwent concurrent retinal and glaucoma procedures with or without cataract surgery, were selected. Outcomes after surgery were judged based on the World Glaucoma Association guidelines on reporting glaucoma surgical trials, comprising functional and surgical parameters.
Results: The IOP reduced by>50% from baseline in all 6 eyes, with one eye developing shallow AC by overstraining and 3 eyes developing transient self-resolving hyphema. Two eyes received additional bevacizumab (n=1) or ranibizumab (n=1) injections for persistent DME at 4 and 5 months after surgery. The final IOP was reduced in all eyes at the final follow-up of 6±1.2 months, with one eye requiring 2 medications for IOP control.
Conclusion: The outcomes after concurrent retinal and glaucoma filtering surgery in NVG may be comparable to those of the traditional stepwise approach to management, provided these are offered on a case-by-case basis.
References
Ramji S, Nagi G, Ansari AS, Kailani O. A systematic review and meta-analysis of randomised controlled trials in the management of neovascular glaucoma: absence of consensus and variability in practice. Graefes Arch Clin Exp Ophthalmol. 2023;261(2):477-501
Sandramouli S, Sihota R, Sood NN. Role of anterior retinal cryoablation in the management of neovascular glaucoma. Documenta Ophthalmologica. 1993; 84(2): 179–185.
Lidder AK, Paranjpe V, Lauter AJ. Management of Neovascular Glaucoma. Int Ophthalmol Clin. 2023; 63(4): 167–183.
Landers JA, Mullany S, Craig JE. Intravitreal bevacizumab improves trabeculectomy survival at 12 months: the bevacizumab in trabeculectomy study—a randomised clinical trial. British Journal of Ophthalmology. 2023: bjo-2023-323526.
Khan SM, Rao A. Trabeculectomy with concurrent intravitreal bevacizumab in neovascular glaucoma. Indian J Ophthalmol. 2024; 72(3): 386–390.
SooHoo JR, Seibold LK, Kahook MY. Recent Advances in the Management of Neovascular Glaucoma. Semin Ophthalmol. 2013; 28(3): 165–172.
Sastry A, Ryu C, Jiang X, Ameri H. Visual Outcomes in Eyes with Neovascular Glaucoma and Anterior Segment Neovascularization Without Glaucoma. Am J Ophthalmol. 2022; 236: 1–11.
José P, Teixeira FJ, Barão R, Sousa DC, Marques RE, Barata ADDO, et al. Trabeculectomy with mitomycin C alone or coupled with intracameral bevacizumab? A 2-year comparative study. British Journal of Ophthalmology. 2022; 106(10): 1399–1405.
Nilforushan N, Es’haghi A, Miraftabi A, Abolfathzadeh N, Banifatemi M. Trabeculectomy in patients with diabetes: subconjunctival Mitomycin C with or without intravitreal bevacizumab. British Journal of Ophthalmology. 2022; 106(5): 648–654.
Liu X, Du L, Li N. The Effects of Bevacizumab in Augmenting Trabeculectomy for Glaucoma. Medicine. 2016; 95(15): e3223.
Vandewalle E, Abegão Pinto L, Van Bergen T, Spielberg L, Fieuws S, Moons L, et al. Intracameral bevacizumab as an adjunct to trabeculectomy: a 1-year prospective, randomised study. British Journal of Ophthalmology. 2014; 98(1): 73–78.
Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of Intravitreal Bevacizumab (Avastin). Ophthalmology. 2007; 114(5): 855–859.
Sinapis, Sinapis CI, Sinapis DI, RoutsiasJG, Pantopoulou A, Baltatzis S, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits. Clinical Ophthalmology. 2011;5: 697-704.
Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal Aflibercept, Bevacizumab, and Ranibizumab. Retina. 2017; 37(10): 1847–1858.
Moisseiev E, Waisbourd M, Ben-Artsi E, Levinger E, Barak A, Daniels T, et al. Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2014; 252(2): 331–337.
Miyake T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ogasawara K, et al. Pharmacokinetics of Bevacizumab and Its Effect on Vascular Endothelial Growth Factor after Intravitreal Injection of Bevacizumab in Macaque Eyes. Investigative Opthalmology & Visual Science. 2010; 51(3): 1606-08.
Ishibashi S. Angiographic Changes in Iris and Iridocorneal Angle Neovascularization After Intravitreal Bevacizumab Injection. Archives of Ophthalmology. 2010; 128(12): 1539-45.
Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, et al. Intravitreal Bevacizumab to Treat Iris Neovascularization and Neovascular Glaucoma Secondary to Ischemic Retinal Diseases in 41 Consecutive Cases. Ophthalmology. 2008; 115(9): 1571-1580.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This is an open-access journal and articles are distributed under the terms of the Creative Commons Attribution Non-Commercial Share-Alike License 4.0. This licence allows users to download and share, remix, tweak and build upon the article for non-commercial purposes, so long as the original authorship is acknowledged and the new creations are licensed under identical terms.